Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 15;11(4):571.
doi: 10.3390/healthcare11040571.

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

Ilaria Cuccu  1 , Ottavia D'Oria  1   2 , Ludovica Sgamba  1 , Emanuele De Angelis  1 , Tullio Golia D'Augè  1 , Camilla Turetta  1 , Camilla Di Dio  1 , Maria Scudo  1 , Giorgio Bogani  3 , Violante Di Donato  1 , Innocenza Palaia  1 , Giorgia Perniola  1 , Federica Tomao  1 , Ludovico Muzii  1 , Andrea Giannini  1
Affiliations
Review

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

Ilaria Cuccu et al. Healthcare (Basel). .

Abstract

Endometrial cancer (EC) is one of the most common gynecological malignancies in Western countries. Traditionally, loco-reginal dissemination and histological characteristics are the main prognostic factors. Nowadays, molecular and genomic profiling showed exciting results in terms of prognostication. According to the data provided by The Cancer Genome Atlas and other studies, molecular and genomic profiling might be useful in identifying patients al low, intermediate, and high risk of recurrence. However, data regarding the therapeutic value are scant. Several prospective studies are ongoing to identify the most appropriate adjuvant strategy in EC patients, especially for those with positive nodes and low volume disease. The molecular classification has offered the possibility to improve the risk stratification and management of EC. The aim of this review is to focus on the evolution of molecular classification in EC and its impact on the research approach and on clinical management. Molecular and genomic profiling might be useful to tailor the most appropriate adjuvant strategies in apparent early-stage EC.

Keywords: endometrial cancer; genetics; molecular; personalized treatment; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jema L.A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Amant F., Mirza M.R., Koskas M., Creutzberg C.L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 2018;143((Suppl. S2)):37–50. doi: 10.1002/ijgo.12612. - DOI - PubMed
    1. Gu B., Shang X., Yan M., Li X., Wang W., Wang Q., Zhang C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol. Oncol. 2021;161:573–580. doi: 10.1016/j.ygyno.2021.01.036. - DOI - PubMed
    1. Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021;31:12–39. doi: 10.1136/ijgc-2020-002230. - DOI - PubMed

LinkOut - more resources